EMED Technologies, an El Dorado Hills, CA-based developer of drug-delivery and innovative infusion-therapy devices, has announced that its subsidiary closed an $8 million equity funding round led by a healthcare company.
Read More:Slang AI Raises $36M in Series B Funding
The funds from the raise will be used to grow the organization, expand its product line, and support strategic initiatives aligned with EMED’s long-term goals in the drug-delivery market.
“This capital raise is an important milestone and highlights the strategic value of this platform within EMED’s broader portfolio,” said Paul Lambert, Chief Executive Officer of EMED Technologies. “It gives the organization the resources to carry out its growth strategy in a focused way while keeping operational flexibility.”
EMED Technologies is a global leader in drug delivery and innovative infusion therapy devices. As a subsidiary of EMED Technologies, the company benefits from EMED’s global expertise, strong governance, and operational support, while continuing to operate with a focused mission, and independent execution. The subsidiary remains aligned with EMED’s long term strategy. It is advancing initiatives that drive sustainable growth, helping serve hundreds of thousands of patients who benefit from EMED’s existing devices and pipeline technologies to achieve better healthcare outcomes.
EMED’s subsidiary structure keeps its core drug-delivery business focused while allowing it to pursue complementary growth opportunities responsibly. This structure maintains strong governance and operational discipline at the parent level, while enabling related initiatives to grow independently without adding risk or distraction to EMED’s main platform.
About EMED Technologies
Founded in 1991 by CEO Paul Lambert, EMED Technologies is a leader in the design, manufacture and distribution of advanced medical devices. The company’s mission is to support patient independence by creating patient-focused systems that improve quality of life, especially for mid- to large-volume subcutaneous infusions. Since its founding, EMED has partnered with patients, clinicians, and pharmaceutical companies to develop, manufacture, and commercialize innovative drug-delivery systems. Under the leadership of Paul Lambert, EMED continues to advance medical technology with solutions that enhance patient safety, improve clinical outcomes, and simplify drug administration for both patients and healthcare professionals.
EMED Technologies specializes in medical devices for subcutaneous infusion systems. Its products are designed to safely and efficiently deliver medications and fluids, especially for patients who need home care or ongoing treatment for chronic conditions. The company offers devices such as the SCIg60, Infuset and VersaRate to support therapies like immune globulin and other injectable treatments. EMED focuses on patient safety, ease of use, and enabling home-based care. Its technology is built to support people who require long-term treatments, particularly medications that must be delivered slowly and consistently over time.
Read More:Humand Raises $66M in Series A Funding
